Nothing Special   »   [go: up one dir, main page]

Ariel et al., 2023 - Google Patents

OPEN ACCESS EDITED BY

Ariel et al., 2023

Document ID
17559965302859331715
Author
Ariel A
Van Der Sluis T
Schlecht-Louf G
et Immunopathologie C
Bonsack M
Riemer A
Mohan N
Wellach K
Özerdem C
Veits N
Förster J
Foehr S
Bonsack M
Riemer A
Veits F
Foehr B
Publication year
Publication venue
Immunity, Cancer and the Microenvironment: Resolving a 3-Way Standoff

External Links

Snippet

High-risk human papillomaviruses (HPVs) are responsible for cervical cancers, and a major proportion of other anogenital and oropharyngeal cancers (1). As of 2018, cervical cancer was the fourth most common cancer in women worldwide and caused> 300,000 deaths …
Continue reading at books.google.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups

Similar Documents

Publication Publication Date Title
Smith et al. Effective treatment of metastatic forms of Epstein-Barr virus–associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy
Liu et al. Increased expression of PD‑L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity
US8252893B2 (en) CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
Long et al. Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition
St Leger et al. Defining the herpes simplex virus-specific CD8+ T cell repertoire in C57BL/6 mice
Masterson et al. CD8+ T cell response to human papillomavirus 16 E7 is able to predict survival outcome in oropharyngeal cancer
Jayshree et al. Cell intrinsic & extrinsic factors in cervical carcinogenesis
CN111936619A (en) Production of HPV-specific T cells
WO2016203577A1 (en) Cytotoxic t-cell epitope peptide and use thereof
US20090232842A1 (en) HPV Vaccine Comprising Peptides From Host Cell Proteins
Gameiro et al. The tumor immune microenvironments of HPV+ and HPV− head and neck cancers
Da Silva et al. Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I: C
US20210205435A1 (en) Materials and methods relating to immunogenic epitopes from human papillomavirus
Luo et al. The impact of inflationary cytomegalovirus‐specific memory T cells on anti‐tumour immune responses in patients with cancer
Tsang et al. Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7
Nakagawa et al. HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein
Rödel et al. Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy
US9547006B2 (en) Correlation of disease activity with clonal expansions of human papillomavirus 16-specific CD8+ T-cells in patients with severe erosive oral lichen planus
Amador-Molina et al. Vaccination with human papillomavirus-18 E1 protein plus α-galactosyl-ceramide induces CD8+ cytotoxic response and impairs the growth of E1-expressing tumors
Koelle Expression cloning for the discovery of viral antigens and epitopes recognized by T cells
Stanke et al. A flow cytometry-based assay to assess minute frequencies of CD8+ T cells by their cytolytic function
Liu et al. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A* 0201-restricted T-cell peptides in cervical cancer patients
Warrino et al. Disease-stage variance in functional CD4+ T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes
Mohan et al. Effects of hypoxia on antigen presentation and T cell-based immune recognition of HPV16-transformed cells
JP2004514449A (en) T cell epitopes of papillomavirus L1 and E7 proteins and their use in diagnosis and therapy